Biomedcode is a Contract Research Organisation (CRO), founded in 2006 as a spin-off company of the Biomedical Sciences Research Center "Alexander Fleming”. The establishment of Biomedcode was the result of the long lasting expertise of Fleming researchers in successfully generating transgenic mouse models that develop symptoms of rheumatoid arthritis, cachexia, and inflammatory bowel disease. βιομεδψοδε
The long standing expertise and scientific excellence of Biomedcode's Board of Directors and Scientific Management Team in the field of inflammatory and autoimmune diseases, as well as the high academic level and professional skills of the company's personnel gives us the potential to address our customers' needs from an expert's point of view providing personalized solutions and advise for top quality drug evaluation services. Biomedcode boasts over 50 years of accumulated experience in immunology research with over 70% of its staff having international post-doctoral & management experience in the UK, Switzerland, France and USA.
Biomedcode's Arthrirtis models (Tg197
were instrumental in providing in vivo proof of principle on the role of TNF in the development of chronic polyarthritis and for predicting the therapeutic value of anti-huTNF antibodies
Armed with the lasting success of these models, and the contined and renewed interest of the pharmaceutical industry to develop second generation anti-TNF therapeutics, the founders of Biomedcode saw a unique opportunity to serve this and other niche markets. Over the years Biomedcode has expanded its interests to include additional humanized mouse models of either spontaneous or induced inflammatory diseases.
Currently, Biomedcode generates, owns and operates unique humanized transgenic mouse models mimicking Rheumatoid Arthritis, Intestinal Inflammation, Psoriasis, Multiple Sclerosis, Osteoporosis
and other diseases
. In addition to its proprietary humanized mouse models Biomedcode also offers a number of standard induced models of disease such as CAIA, EAE, induced colitis
, and others. Moreover, Biomedcode employs state of the art technological platforms for comprehensive phenotyping of disease progression and response to therapy.
To sustain its lead in preclinical drug evaluation outsourcing services, Biomedcode maintains a highly active R&D program
that aims to generate and exploit novel humanized animal disease models. In the context of its R&D activities, Biomedcode
is a partner in several European FP6 and FP7 consortia
, such as the Masterswitch and Inflacare Integrated projects and the MUGEN Network of Excellence, and plans to expand these collaborations while intensifying its R&D efforts.
Our mission is to provide a customer and quality-oriented, process-driven approach tailored to meet individual customer outsourcing needs.